总部位于巴黎的 Orakl Oncology 完成 3400 万美元 A 轮融资，由 Norrsken VC 和 Singular 共同领投。《欧洲生物技术》报道，此轮融资旨在预测癌症药物在进入患者体内前的表现，使该公司总融资额达到 5000 万美元。
Paris-based Orakl Oncology has raised a $34M Series A co-led by Norrsken VC and Singular. It grows copies of patients’ tumours in the lab, tests drugs on them and uses AI to predict trial results. It will expand into lung and gastric cancer. Paris-based Orakl Oncology has raised a $34M Series A to predict how cancer drugs will perform before they reach patients, European Biotechnology reported.
Orakl 于 2023 年从法国癌症中心 Gustave Roussy 分拆而出。它在实验室培育患者肿瘤的微型副本（称为类器官），并在其上测试药物。随后，它将这些结果与患者病历相结合，训练 AI 模型以预测药物在临床试验中的表现。
The round was co-led by Swedish investor Norrsken VC and French firm Singular, taking total funding to $50M. Orakl was spun out of French cancer centre Gustave Roussy in 2023. It grows small copies of patients’ tumours in the lab, called organoids, and tests drugs on them. It then combines those results with patients’ medical records to train AI that predicts how a drug will do in clinical trials.
Norrsken 称该系统准确率达 90%。一份 4 月发布的预印本（尚未经过同行评审）在 23 项既往结直肠癌和胰腺癌试验上测试了该模型。其对患者无进展生存期的预测平均偏差为 0.82 个月。
Norrsken says the system is 90% accurate. An April preprint, not yet peer-reviewed, tested the model on 23 past colorectal and pancreatic cancer trials. Its forecasts of how long patients went without their cancer worsening were off by 0.82 months on average.
该模型在八个案例中有七个选出了更优疗法。但这些测试是回顾已结束的试验，且大多涉及标准化疗。该模型对新型药物的处理能力仍有待验证。
It also picked the better treatment in seven of eight cases. But those tests looked back at trials that had already finished, and most involved standard chemotherapy. How the model handles newer drugs still needs to be proven.
资金将用于产出五倍实验室数据、拓展肺癌和胃癌领域，并在美国和英国组建团队。Norrsken 称全球 20 大药企中有 18 家正在与 Orakl 洽谈，7 月该公司已获得测试赛诺菲四款抗癌药物的权利。
The money will go into producing five times more lab data, expanding into lung and gastric cancers, and opening teams in the US and UK. Norrsken says 18 of the world’s 20 biggest drugmakers are in talks with Orakl, and in July it won rights to test four of Sanofi’s cancer drugs.
Orakl 加入了利用 AI 从事生物学研究的巴黎初创企业浪潮，其中包括 10 月融资 2500 万美元的 Rivercell。Singular 今年还领投了巴黎医疗初创企业 Lucis 的 2000 万美元融资，而美国药物设计初创企业 Chai Discovery 于 7 月融资 4 亿美元。
Orakl joins a wave of Paris startups using AI in biology, including Rivercell, which raised $25M in October. Singular also led a $20M round in Paris health startup Lucis this year, while US drug-design startup Chai Discovery raised $400M in July.